Compare AbCellera Biologics Inc (ABCL) vs CDW Corp. (CDW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs CDW Corp. — how do they compare? AbCellera Biologics Inc trades at $7.13 (market cap $2.35B), while CDW Corp. trades at $137.92 (market cap $17.79B). The key difference: CDW Corp. is far larger — about 7.6× AbCellera Biologics Inc's market cap, and CDW Corp. pays a 1.81% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | CDW | |
|---|---|---|
Market Cap | $2.35B | $17.79B |
Sector | Health | Technology |
52-Week High | $8.12 | $182.18 |
52-Week Low | $2.78 | $99.30 |
Enterprise Value | $1.99B | $23.00B |
Dividend Yield | — | 1.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
CDW trades at $139.23, up 4.39% today, near its consensus price target of $142.17. The stock shows a bullish technical trend with strong moving averages, while fundamentals reflect steady revenue of $22.42B in 2025 and robust profitability with a 44.16% ROE. Recent news highlights AI infrastructure demand fueling growth, and the company increased its share repurchase program by $1 billion in May 2026.
Outlook is positive with analyst consensus strongly bullish (70.59% buy ratings), though risks include margin pressure and competitive threats. The stock offers value with a P/E of 16.34 and growth potential from AI adoption, but investors should monitor execution on earnings targets and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About CDW Corp.
CDW Corp is a value-added reseller operating in the U.S. (95% of sales) and Canada (5%). The company has more than 100,000 products on its line of cards that range from notebooks to data center software. Roughly half of CDW's revenue comes from midsize and large businesses, with the remaining from small businesses, government agencies, education institutions, and health-care organizations.
Read more on CDW →
